Blog
RSS FeedPosted by Michael Wonder on 21 Jun 2023
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer
21 June 2023 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) in combination with lenvatinib ...
Posted by Michael Wonder on 21 Jun 2023
Dapagliflozin propanediol monohydrate for the treatment of adults with chronic heart failure with preserved or mildly reduced ejection fraction
21 June 2023 - NICE has published final evidence-based recommendations on the use of dapagliflozin propanediol monohydrate for the treatment ...
Posted by Michael Wonder on 17 Jun 2022
NICE recommends new targeted treatment for early breast cancer
16 June 2022 - NICE has provisionally approved a new treatment for early breast cancer that it says will benefit ...
Posted by Michael Wonder on 12 Oct 2021
NICE guidance on inclisiran should be reconsidered
12 October 2021 - Recommendation is premature without data on cardiovascular outcomes. ...
Posted by Michael Wonder on 07 May 2021
Avelumab not recommended as a maintenance treatment of urothelial cancer after platinum-based chemotherapy
7 May 2021 - NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of locally advanced or ...
Posted by Michael Wonder on 28 Jun 2020
NICE's evaluations of medicines authorized by EMA with conditional marketing authorization or under exceptional circumstances
25 June 2020 - Products which received conditional marketing authorisation or authorisation in exceptional circumstances by European Medicines Agency up to ...
Posted by Michael Wonder on 23 Jun 2020
MHRA extends access to Santhera's DMD drug via the EAMS
23 June 2020 - The UK’s Medicines and Healthcare products Regulatory Agency has renewed for a further year the Early ...
Posted by Michael Wonder on 27 Mar 2019
600 years’ supply of cystic fibrosis drug destroyed in price row
27 March 2019 - Nearly 8,000 packs of Orkambi, the breakthrough medicine for cystic fibrosis, have been destroyed by the ...
Posted by Michael Wonder on 01 Oct 2018
NHS England agrees to fund Janssen’s Symtuza
1 October 2018 - NHS England has agreed to provide funding for Janssen’s Symtuza, a once-daily darunavir-based single tablet regimen ...
Posted by Michael Wonder on 12 Dec 2017
Final NHS ‘no’ for obesity pill Mysimba
12 December 2017 - An appeal to get NHS funding for Mysimba as a means for controlling weight has failed, ...
Posted by Michael Wonder on 13 Jul 2017
NICE backs Humira, Enbrel and Stelara for plaque psoriasis in children
13 July 2017 - AbbVie’s Humira, Pfizer’s Enbrel, and Janssen’s Stelara are being recommended as options for treating plaque psoriasis ...
Posted by Michael Wonder on 13 Jun 2017
NICE publishes appraisal consultation document for inotuzumab ozogamicin
13 June 2017 - The Department of Health has asked NICE to produce guidance on the use inotuzumab ozogamicin in the ...
Posted by Michael Wonder on 23 May 2017
US pharma giant Merck & Co. accused of blocking cheaper arthritis drugs for the NHS
23 May 2017 - The US pharmaceuticals giant Merck & Co is accused of abusing its dominance of the market ...
Posted by Michael Wonder on 13 Nov 2016
Life-extending breast cancer drug approved by NICE in draft guidance
3 November 2016 - People with advanced breast cancer are set to benefit from a life-extending drug as NICE says it ...
Posted by Michael Wonder on 09 Oct 2016
NICE backs use of Forxiga in triple therapy for diabetes
7 October 2016 - NICE has now published final draft guidelines endorsing NHS use of AstraZeneca's Forxiga for treating type ...